Clinical Trial Update: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin [Phase 2]

View source ↗

Summary

This update notes a phase 2 trial evaluating MEN1611 alone or in combination with eribulin for PIK3CA/PTEN-altered advanced/metastatic breast cancer; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)
• MEN1611 (MEN1611)

Snippet

Sponsor: MedSIR | Conditions: Breast Cancer, Advanced Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING